We are thrilled to see the NC-202™ helping Muna Therapeutics drug target discovery and validation program. When doing drug screens, you want to have the correct amount of cells in your plates every time 🔬
A proud moment for #Muna_Tx colleagues, who secured a 1.5 million DKK Danish InnoBooster grant to support work on our newest portfolio program, a drug target identified by MiND-MAP, Muna's all-in-human target discovery and validation platform. We found that the target and its interactome are differentially expressed in #Alzheimers_Diease compared to "resilient" human brains analyzed postmortem using spatial transcriptomics. Understanding mechanisms underlying resilience to cognitive impairment, despite the presence of misfolded proteins that are hallmarks of Alzheimer's, is a focus of #Muna_Tx's ongoing work with MiND-MAP to discover and validate drug targets for AD and other #neurodegenerative_diseases. Congratulations, #Muna_Tx team! #neurodegeneration #Alzheimers #biotech #drug_discovery #neurology #neuroscience
